---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-014859"
form_type: "8-K"
ticker: "ARWR"
cik: "0000879407"
company_name: "ARROWHEAD PHARMACEUTICALS, INC."
filed_at: "2023-05-02T23:59:59+00:00"
generated_at: "2026-06-16T04:22:16.477606+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Arrowhead Q2 net income $48.7M ($0.45 diluted); milestones from Takeda, GSK, positive ARO-RAGE data

## Summary
- Revenue $146.3M, operating income $48.2M, net income $48.7M ($0.45 diluted), up from $44.4M ($0.41) in prior year.
- Earned $40M milestone from Takeda for fazirsiran Phase 3 start; $30M from GSK for Phase 2b of GSK4532990 (NASH).
- Phase 1/2 ARO-RAGE: mean max 80% reduction in serum sRAGE after two 92 mg doses; no serious AEs; supports lung delivery platform.
- Regained rights to ARO-PNPLA3 from Janssen; FDA Fast Track for ARO-APOC3 for familial chylomicronemia syndrome.
- Cash and investments $559.8M vs $482.3M at Sept 30, 2022; R&D Day June 1, 2023; ARO-SOD1 on track for Q3 CT filing.

## SEC filing metadata
- accession: 0001628280-23-014859
- form_type: 8-K
- ticker: ARWR
- cik: 0000879407
- company_name: ARROWHEAD PHARMACEUTICALS, INC.
- filed_at: 2023-05-02T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/879407/000162828023014859/0001628280-23-014859-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/879407/000162828023014859/arwr-20230502.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-014859
- JSON: https://secwatch.observer/filing/0001628280-23-014859.json
- Plain text: https://secwatch.observer/filing/0001628280-23-014859.txt

## Key facts
- Earnings Releases
  ARROWHEAD PHARMACEUTICALS, INC. reported its fiscal second quarter ended March 31, 2023 results: revenue $ 146,267, net income $ 48,675, EPS $ 0.45.
  - Period: its fiscal second quarter ended March 31, 2023
  - Revenue: $ 146,267
  - Net income: $ 48,675
  - EPS: $ 0.45
  - Result: reported results
  source text: in The New England Journal of Medicine Selected Fiscal 2023 Second Quarter Financial Results Three Months Ended March 31, OPERATING SUMMARY 2023 2022 (unaudited) Revenue $ 146,267 $ 151,805 Operating Expenses: Research and development 74,881 75,985 General and administrative expenses 23,221 34,267 Total Operating Expenses 98,102 110,252 Operating income
  evidence_url: https://www.sec.gov/Archives/edgar/data/879407/000162828023014859/0001628280-23-014859-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.